Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Contribute

España

India

Italia

대한민국

日本

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics

Research

My Stocks

Tools

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Trade Ideas

Unusual Options Activity

Heatmaps

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Calculators

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

Cosmo Pharmaceuticals

CMOPFOTCPK

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$69.62

0.370.53%

At close: -

$96.50

26.8838.61%

After Hours: May 3, 9:29 AM EDT

Cosmo Pharmaceuticals (CMOPF) Forecast

News

Earnings Cosmo Pharmaceuticals (CMOPF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for Cosmo Pharmaceuticals (OTC:CMOPF) Stock

Cosmo Pharmaceuticals Stock (OTC: CMOPF)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, March 22, 2023

Medtronic To Boost AI Innovation With New Platform Introduction; Strategic Collaboration With Cosmo Pharmaceuticals And Nvidia Delivers The GI Genius AI Access Platform Designed To Accelerate AI Innovation For Healthcare
Happy Mohamed

Friday, July 06, 2018

Cosmo Pharmaceuticals Announced FDA Has Approved Actavis (TEVA) Generic Version Of Uceris; Co. Says It Will Continue To Defend And Enforce Patent Rights On Uceris, Says If Teva Decides To Launch At Risk, It Would Expose Teva To Pay Significant Damages
Benzinga

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap